Advertisement

Laboratory Monitoring of Anticoagulant therapy

  • Aastha Gupta
  • D. S. Udayakumar
  • Renu Saxena
Chapter

Abstract

Worldwide, millions of patients are put on short-term and long-term anticoagulant therapy for several thrombotic indications. The critical balance of the inherent risk of bleeding and the anticoagulant effect of these drugs needs to be maintained. There is an increasing use of new oral anticoagulants apart from the conventional agents such as heparin and vitamin K antagonists, and it is imperative to know the appropriate assay(s) that are used for each drug monitoring. Hence, both clinical and laboratory personnel should be aware of assays to monitor different anticoagulant therapy and various physiological as well as laboratory variables affecting these results.

References

  1. 1.
    Peacock W, Rafique Z, Singer A. Direct-acting oral anticoagulants: practical considerations for emergency medicine physicians. Emer Med Int. 2016;2016:1–13.CrossRefGoogle Scholar
  2. 2.
    Ruff C, Giugliano R, Braunwald E, Hoffman E, Deenadayalu N, Ezekowitz M, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955–62.CrossRefGoogle Scholar
  3. 3.
    Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:165–86.CrossRefGoogle Scholar
  4. 4.
    Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol. 2006;133(1):19–34.CrossRefGoogle Scholar
  5. 5.
    Zehnder J, Prince E, Jin J. Controversies in heparin monitoring. Am J Hematol. 2012;87(Suppl 1):S137–40.CrossRefGoogle Scholar
  6. 6.
    Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range. Arch Int Med. 2001;161:385–91.CrossRefGoogle Scholar
  7. 7.
    Vandiver JW, Vondracek TG. AntifactorXa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012;32:546–58.CrossRefGoogle Scholar
  8. 8.
    Funk DM. Coagulation assays and anticoagulant monitoring. Hematology. 2012;2012:460–5.PubMedGoogle Scholar
  9. 9.
    Makris M, Van Veen J, Tait C, Mumford A, Laffan M. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2012;160(1):35–46.CrossRefGoogle Scholar
  10. 10.
    Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(Suppl):8–21.CrossRefGoogle Scholar
  11. 11.
    Breckenridge A, Orme M, Wesseling H, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther. 1974;15:424–30.CrossRefGoogle Scholar
  12. 12.
    Favaloro EJ, Adcock DM. Standardization of the INR: how good is your laboratory’s INR and can it be improved? Semin Thromb Hemost. 2008;34(7):593–603.CrossRefGoogle Scholar
  13. 13.
    Dorfman DM, Goonan EM, Boutilier MK, Jarolim P, Tanasijevic M, Goldhaber S. Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation. Vasc Med. 2005;10(1):23–7.CrossRefGoogle Scholar
  14. 14.
    Lewis S, Bain B, Bates I, Dacie J, Dacie J. Dacie and Lewis practical haematology. Philadelphia: Churchill Livingstone; 2006.Google Scholar
  15. 15.
    Conway S, Hwang A, Ponte C, Gums J. Laboratory and clinical monitoring of direct-acting oral anticoagulants: what clinicians need to know. Pharmacotherapy. 2017;37(2):236–48.CrossRefGoogle Scholar
  16. 16.
    Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11(1):8.CrossRefGoogle Scholar
  17. 17.
    Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World J Methodol. 2015;5(4):212.CrossRefGoogle Scholar
  18. 18.
    Gous T, Couchman L, Patel J, Paradzai C, Arya R, Flanagan R. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit. 2014;36(5):597–605.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Aastha Gupta
    • 1
  • D. S. Udayakumar
    • 1
  • Renu Saxena
    • 1
  1. 1.Department of HematologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations